Market analyst Raja Venkatraman has highlighted SBI Cards, Bharti Hexacom, and Dr. Lal PathLabs as stocks of interest following recent market volatility. Investors may evaluate these companies based on their technical patterns and current sector dynamics. The Nifty 50 recently closed at 24,052 amid global concerns, making specific stock performance key to watch.
Following a session of market pressure where the Nifty 50 fell to 24,052 and the Sensex declined by 561 points, market focus has shifted toward individual stock performance. Analyst Raja Venkatraman has pointed to SBI Cards, Bharti Hexacom, and Dr. Lal PathLabs, noting technical indicators that may be relevant for investors evaluating these sectors.
SBI Card and Payment Services
As one of India’s major credit card issuers, SBI Card has recently seen technical patterns that market watchers often correlate with potential consolidation breakouts. The stock currently trades with a price-to-earnings (P/E) ratio of 28.06, well below its 52-week high of ₹965. While the technical outlook suggests interest, the company faces inherent business challenges. As a provider of unsecured credit, SBI Card is sensitive to macroeconomic shifts that affect consumer spending and repayment capabilities. Investors often monitor credit quality metrics and the company’s ability to manage asset quality amid fluctuating interest rate environments.
Bharti Hexacom
The telecommunications sector, represented here by Bharti Hexacom, operates with a focus on specific regions including Rajasthan and the North East. The stock trades at a P/E of 46.79, compared to its 52-week peak of ₹1,955.60. From a business perspective, the company is susceptible to changes in Average Revenue Per User (ARPU) and ongoing competitive intensity within the Indian telecom landscape. Any regulatory changes affecting spectrum pricing or infrastructure investment remain factors that can impact financial performance over the long term.
Dr. Lal PathLabs
Dr. Lal PathLabs continues to be a prominent player in the diagnostic healthcare space, maintaining a P/E ratio of 57.40. The stock has been trading near its 52-week high of ₹1,803.60. For diagnostic firms, profit margins are often dictated by competitive pricing pressures and the cost of maintaining high-tech laboratory networks. As the healthcare industry consolidates, investors typically track the company’s ability to sustain volume growth while managing the costs associated with expanding their service footprint.
With the broader market showing consolidation between 23,800 and 24,300, the performance of these companies will likely be influenced by their respective sector trends. Investors may monitor future quarterly results to see how these firms manage the specific risks mentioned, including unsecured lending exposure for SBI Card, ARPU stability for Bharti Hexacom, and pricing competition for Dr. Lal PathLabs.